Aptiv Solutions, a biopharmaceutical and medical device development services company and pioneer in adaptive clinical trial design, simulation and execution, announces publication of a Tufts Center ...

Drug developers plan to improve R&D management and operations in 2015 in order to cut development costs and avoid the glare of payers increasingly intent on containing drug prices, the Tufts Center ...

On February 23 2022, the European Commission published a proposal of the Corporate Sustainability Due Diligence Directive (CSDD or the Directive), which would require both EU and non-EU companies ...

The Tufts Center for the Study of Drug Development (Tufts CSDD) is a non-profit, multi-disciplinary academic research group located on the campus of Tufts University. Tufts CSDD provides strategic ...

Dublin, March 18, 2025 (GLOBE NEWSWIRE) -- The "Understanding the Implications of the New Directive on Corporate Sustainability Due Diligence (CSDD) Training Course" training has been added to ...

NOTTINGHAM, England--(BUSINESS WIRE)--Tufts Center for the Study of Drug Development (CSDD) today published a white paper sharing study results that indicate Quotient Sciences’ Translational ...

Dublin, Feb. 12, 2026 (GLOBE NEWSWIRE) -- The "Understanding the Implications of the New Directive on Corporate Sustainability Due Diligence (CSDD) Training Course (Apr 30, 2026)" training has been ...

While personalized medicines have grown to 13% of all drugs marketed in the U.S.—up from 10% in 2010—biopharmas still face hurdles that impede faster market uptake, the Tufts Center for the Study of ...

A vigorous development pipeline predicts that the recent increased pace of biotech approvals will continue for the following decade, showing that biopharmaceuticals accounted for 35% of all new drug ...

Aptiv Solutions announces publication of a Tufts Center for the Study of Drug Development (CSDD) report on the adoption and impact of adaptive trial designs. Adaptive designs allow pre-planned ...